Compare Viatris Inc (VTRS) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Viatris Inc trades at $16.28 (market cap $18.69B), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Viatris Inc pays a 2.95% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| VTRS | XLY | |
|---|---|---|
Market Cap | $18.69B | — |
Sector | Health | — |
52-Week High | $17.86 | $124.52 |
52-Week Low | $9.49 | $105.64 |
Enterprise Value | $30.80B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
XLY trades at $118.02, down 1.38% today, with a bullish technical signal from moving averages but overbought RSI readings. Analyst consensus is unanimously positive, with a 100% buy rating. The ETF focuses on consumer discretionary stocks, benefiting from economic trends favoring the sector.
Outlook remains favorable due to strong analyst support and sector momentum, though overbought conditions and consumer spending sensitivity pose near-term risks. Long-term growth hinges on sustained economic strength and discretionary demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
